RBOT logo

Vicarious Surgical (RBOT) Company Overview

Profile

Full Name:

Vicarious Surgical Inc.

Sector:

Healthcare

Country:

United States

IPO:

September 4, 2020

Indexes:

Not included

Description:

RBOT, developed by Vicarious Surgical, is a robotic surgical system designed to enhance minimally invasive surgeries. It combines advanced robotics and virtual reality to assist surgeons, improving precision and patient outcomes while reducing recovery times. The technology aims to transform traditional surgical practices for better healthcare solutions.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Mar 4, 2025

Recent annual earnings:

Mar 4, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 13, 2024

Analyst ratings

Recent major analysts updates

Aug 13, 24 Piper Sandler
Neutral
Mar 5, 24 Piper Sandler
Neutral
Dec 4, 23 Morgan Stanley
Equal-Weight
Nov 14, 23 Canaccord Genuity
Hold
Nov 14, 23 BTIG
Neutral
May 31, 23 Canaccord Genuity
Buy
Jul 18, 22 BTIG
Buy
May 10, 22 Piper Sandler
Neutral
Mar 4, 22 Piper Sandler
Neutral
Mar 4, 22 Canaccord Genuity
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Vicarious Surgical?
  • Does Vicarious Surgical pay dividends?
  • What sector is Vicarious Surgical in?
  • What industry is Vicarious Surgical in?
  • What country is Vicarious Surgical based in?
  • When did Vicarious Surgical go public?
  • Is Vicarious Surgical in the S&P 500?
  • Is Vicarious Surgical in the NASDAQ 100?
  • Is Vicarious Surgical in the Dow Jones?
  • When was Vicarious Surgical's last earnings report?
  • When does Vicarious Surgical report earnings?
  • Should I buy Vicarious Surgical stock now?

What is the ticker symbol for Vicarious Surgical?

The ticker symbol for Vicarious Surgical is NYSE:RBOT

Does Vicarious Surgical pay dividends?

No, Vicarious Surgical does not pay dividends

What sector is Vicarious Surgical in?

Vicarious Surgical is in the Healthcare sector

What industry is Vicarious Surgical in?

Vicarious Surgical is in the Medical Devices industry

What country is Vicarious Surgical based in?

Vicarious Surgical is headquartered in United States

When did Vicarious Surgical go public?

Vicarious Surgical's initial public offering (IPO) was on September 4, 2020

Is Vicarious Surgical in the S&P 500?

No, Vicarious Surgical is not included in the S&P 500 index

Is Vicarious Surgical in the NASDAQ 100?

No, Vicarious Surgical is not included in the NASDAQ 100 index

Is Vicarious Surgical in the Dow Jones?

No, Vicarious Surgical is not included in the Dow Jones index

When was Vicarious Surgical's last earnings report?

Vicarious Surgical's most recent earnings report was on Mar 4, 2025

When does Vicarious Surgical report earnings?

The date for Vicarious Surgical's next earnings report has not been announced yet

Should I buy Vicarious Surgical stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions